Clinical Implication of Highly Sensitive Detection of the BRAFV600E Mutation in Fine-Needle Aspirations According to the Thyroid Bethesda System in Patients With Conventional Papillary Thyroid Carcinoma

被引:12
|
作者
Seo, Jae Young [1 ,2 ,3 ]
Choi, Jong Rak [4 ]
Moon, Hee Jung [1 ,2 ]
Kim, Eun-Kyung [1 ,2 ]
Han, Kyung Hwa [5 ]
Kim, Hyunki [6 ,7 ]
Kwak, Jin Young [1 ,2 ]
机构
[1] Yonsei Univ, Coll Med, Severance Hosp, Dept Radiol, Seoul 120749, South Korea
[2] Yonsei Univ, Coll Med, Severance Hosp, Res Inst Radiol Sci, Seoul 120749, South Korea
[3] Konyang Univ, Coll Med, Konyang Univ Hosp, Dept Radiol, Seoul, South Korea
[4] Yonsei Univ, Coll Med, Severance Hosp, Dept Lab Med, Seoul 120749, South Korea
[5] Yonsei Univ, Coll Med, Med Res Ctr, Biostat Collaborat Unit, Seoul 120749, South Korea
[6] Yonsei Univ, Coll Med, Severance Hosp, Dept Pathol, Seoul 120749, South Korea
[7] Yonsei Univ, Coll Med, Severance Hosp, Res Inst Radiol Sci, Seoul 120749, South Korea
来源
基金
新加坡国家研究基金会;
关键词
proto-oncogene proteins BRAF; mutation; thyroid cancer; papillary; biopsy; fine-needle; cytology; DIAGNOSTIC-ACCURACY; PREVALENT AREA; NODULES; BIOPSY; BRAF; ULTRASOUND; SAMPLES; IMPROVES; PCR;
D O I
10.1177/0003489414560433
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background: We investigated the additional diagnostic yield of the mutation test and evaluated the frequency of the BRAF mutation in conventional PTC (cPTC) according to ultrasound (US) features and the Bethesda System for Reporting Thyroid Cytopathology (BSRTC) based on the BRAF(V600E) mutation status. Materials and Methods: During the study period, 279 patients who underwent FNA with an additional BRAF(V600E) mutation test were diagnosed as cPTC after surgery. We analyzed the association between the mutation and several clinical factors. Results: Of the 279 cPTCs, 250 (89.6%) had the BRAF(V600E) mutation. The BRAF mutation test was helpful in diagnosing an additional 19% (53/279) of cPTCs. The frequency of the BRAF mutation in cPTCs with suspicious US features was higher than that of cPTCs with negative US features regardless of the BSRTC. Conclusions: Suspicious US features may be helpful in deciding whether an additional BRAF(V600E) mutation test should be done in thyroid nodules with indeterminate cytology.
引用
收藏
页码:392 / 399
页数:8
相关论文
共 50 条
  • [21] Investigation of the effect of BRAFV600E mutation on the clinical outcome in the group of patients with papillary thyroid carcinoma
    Hartmanova, M.
    Taborska, K.
    Sykorova, P.
    Kracmerova, T.
    Vlcek, P.
    Dvorakova, S.
    Sykorova, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2016, 43 : S222 - S222
  • [22] BRAFV600E mutation in fine-needle aspiration aspirates: Association with poorer prognostic factors in larger papillary thyroid carcinomas
    Lee, Ji In
    Jang, Hye Won
    Kim, Sun Wook
    Kim, Jong-Won
    Oh, Young Lyun
    Chung, Jae Hoon
    HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2013, 35 (04): : 548 - 553
  • [23] Clinical Manifestations and Gene Expression in Patients with Conventional Papillary Thyroid Carcinoma Carrying the BRAFV600E Mutation and BRAF Pseudogene
    Lin, Jiunn-Diann
    Fu, Shuai-Shuai
    Chen, Jui-Yu
    Lee, Chen-Hsen
    Chau, Wing-Keung
    Cheng, Chao-Wen
    Wang, Yuan-Hung
    Lin, Yuh-Feng
    Fang, Wen-Fang
    Tang, Kam-Tsun
    THYROID, 2016, 26 (05) : 691 - 704
  • [24] Animal Model of the Papillary Thyroid Carcinoma Induced by BRAFV600E Mutation
    Rusinek, D.
    Chmielik, E.
    Kowal, M.
    Swierniak, M.
    Kowalska, M.
    Oczko-Wojciechowska, M.
    Przeorek, C.
    Widlak, W.
    Jarzab, B.
    EUROPEAN JOURNAL OF CANCER, 2012, 48 : S166 - S167
  • [25] Expressions of miRNAs in papillary thyroid carcinoma and their associations with the BRAFV600E mutation
    Huang, Yongbo
    Liao, Denghui
    Pan, Lingxiao
    Ye, Runyi
    Li, Xiaoxi
    Wang, Shenming
    Ye, Caisheng
    Chen, Liuhua
    EUROPEAN JOURNAL OF ENDOCRINOLOGY, 2013, 168 (05) : 675 - 681
  • [26] The BRAFV600E mutation analysis and risk stratification in papillary thyroid carcinoma
    Scheffel, Rafael Selbach
    de Cristo, Ana Patricia
    Romitti, Mirian
    Ferreira Vargas, Carla Vaz
    Ceolin, Lucien
    Zanella, Andre B.
    Dora, Jose Miguel
    Maia, Ana Luiza
    ARCHIVES OF ENDOCRINOLOGY METABOLISM, 2020, 64 (06): : 751 - 757
  • [27] Diagnostic efficacy of brafv600e immunocytochemistry in thyroid aspirates in bethesda category iv and papillary thyroid carcinoma
    Anand, Nidhi
    Agrawal, Tushar
    Gupta, Anurag
    Shukla, Saumya
    Pradhan, Roma
    Husain, Nuzhat
    JOURNAL OF CYTOLOGY, 2021, 38 (03) : 113 - 119
  • [28] Preoperative BRAFV600E mutation detection in thyroid carcinoma by immunocytochemistry
    Swan, Kristine Zoylner
    Madsen, Stine Horskaer
    Bonnema, Steen Joop
    Nielsen, Viveque Egsgaard
    Jespersen, Marie Louise
    APMIS, 2022, 130 (11) : 627 - 636
  • [29] Clinical implications of the extent of BRAFV600E alleles in patients with papillary thyroid carcinoma
    Liu, Lihua
    Chang, Jae Won
    Jung, Seung-Nam
    Park, Hee Sung
    Oh, Taejeong
    Lim, Young Chang
    Koo, Bon Seok
    ORAL ONCOLOGY, 2016, 62 : 72 - 77
  • [30] Clinicopathological significance of BRAFV600E mutation in Uyghur Chinese patients with papillary thyroid carcinoma
    Wen, Hao
    Aizezi, Abudureyinnu
    Yasenjiang, Maimaiti
    Sailike, Magaoweiya
    Wufuer, Yimaer
    INTERNATIONAL JOURNAL OF CLINICAL AND EXPERIMENTAL PATHOLOGY, 2016, 9 (01): : 200 - 207